Revenue Growth QoQ: DURECT Corp (DRRX)

durect.com (DRRX) - corporate logo

DURECT Corporation develops liver therapy medications, focusing on patients with alcoholic hepatitis and the drug Larsucosterol. Quarterly sales dynamics reflect current trends, with the value stabilizing at -79.60. However, a lack of profitability and high R&D expenses are creating a serious liquidity deficit. The company's prospects rely on Larsofanel, which is capable of blocking inflammation genes without the need for an organ transplant.

DRRX (DURECT Corp.) Quarterly Revenue Growth Rate history from 07/04/2022 to 09/27/2025

durect.com (DRRX) - metric breakdowns and financial figures

- company stock exchange capitalization indicators:
- cash and cash flow indicators:
General company analysis:DURECT Corp. (DRRX)
Flagship merchandise of DURECT Corporation

Investors must evaluate the asset's fundamental stability by analyzing sales growth rates, which drive liquidity inflows and market momentum. This quarterly revenue chart reveals business acceleration phases, which for DURECT Corporation (DRRX) is confirmed by the retention of key biochemists and experts ensuring the steady development of long-term projects in liver disease therapy.